Mais de 800 mil pessoas se cadastraram para vacinação contra Covid-19 no Ceará, diz Sesa globo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globo.com Daily Mail and Mail on Sunday newspapers.
Date Time
New clubroot strains show genetic resistance isn’t enough to protect canola, say researchers
Nine new strains of clubroot a disease that can kill canola crops have been discovered in Western Canadian fields by University of Alberta researchers.
While that’s not good news for producers, the discovery shows how important it is to build a multi-pronged strategy for protecting their crops, not relying solely on canola plants bred to resist the disease, said lead researcher Keisha Hollman.
The discovery of the new pathogens in canola fields tested across Alberta, Saskatchewan and Manitoba in 2017 and 2018 means resistance breakdown first discovered in 2013 is growing.
Horgan responded that making sure communities have treatment capacity is a top priority, and the government wants to see the facility built. “I’m not aware the project has been stopped,” he said. “I am aware it has not yet begun.”
In a March 4 letter to three cabinet ministers Indigenous Relations and Reconciliation Minister Murray Rankin; Agriculture, Food and Fisheries Minister Lana Popham; and Mental Health and Addictions Minister Sheila Malcolmson Cheslatta Carrier Chief Corrina Leween criticized the Agricultural Land Commission’s decision to reject plans to build the treatment centre and asked for urgent action.
“The decision fails to uphold your government’s commitments to address the opioid crisis on an urgent basis, to close the systemic gaps in medical and health services for First Nations people in the north, to implement the [Truth and Reconciliation Commission] Calls to Action, and to honour the UN Declaration on the Rights of Indigenous Peoples,”
Featured image of Richard Becker, MD, taken by Colleen Kelley/UC Creative + Brand.
/University Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.
Why?
Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don t put up a paywall – we believe in free access to information of public interest.
Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more here
(0)
Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the company has initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study (Assessment of KAN-101 in Celiac Disease), a Phase 1 clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease. Initiation of the MAD cohort enrollment follows completion of the first two single-ascending dose (SAD) cohorts in the trial, with the third SAD cohort actively dosing patients.
KAN-101, Anokion s lead antigen-specific drug product candidate, aims to re-educate immune cells to not respond to gluten antigens. The ACeD study is a randomized, double-blind, placebo-controlled Phase 1 trial that will enroll a total of up to 40 patients with celiac disease who are on a gluten free diet. The study is composed of two parts. In